News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
354,620 Results
Type
Article (28263)
Company Profile (89)
Press Release (326240)
Multimedia
Podcasts (55)
Webinars (14)
Section
Business (101117)
Career Advice (1182)
Deals (15491)
Drug Delivery (68)
Drug Development (51467)
Employer Resources (84)
FDA (7925)
Job Trends (7664)
News (165803)
Policy (17423)
Tag
2027 BioCapital Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (1)
2027 Genetown Standard (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (1489)
Academic (1)
Accelerated approval (42)
ADA (22)
Adcomms (23)
Allergies (73)
Alliances (26460)
ALS (143)
Alzheimer's disease (992)
Antibody-drug conjugate (ADC) (599)
Approvals (8272)
Artificial intelligence (522)
ASCO (335)
Autoimmune disease (241)
Automation (31)
Bankruptcy (138)
Best Places to Work (6627)
BIO (48)
Biologics (1)
BIOSECURE Act (5)
Biosimilars (157)
BioSpace Insights (54)
Biotechnology (73)
Bladder cancer (225)
Brain cancer (85)
Breast cancer (893)
Cancer (6979)
Cardiovascular disease (250)
Career advice (1021)
Career pathing (31)
CAR-T (322)
CDC (30)
Celiac Disease (2)
Cell therapy (718)
Cervical cancer (60)
Clinical research (45549)
Collaboration (1555)
Commercialization (3)
Company closure (6)
Compensation (547)
Complete response letters (76)
COVID-19 (1193)
CRISPR (55)
C-suite (650)
Cystic fibrosis (59)
Data (6104)
Decentralized trials (3)
Denatured (8)
Depression (88)
Dermatology (58)
Diabetes (333)
Diagnostics (4838)
Digital health (39)
Diversity (7)
Diversity, equity & inclusion (25)
Drug discovery (232)
Drug pricing (86)
Drug shortages (15)
Duchenne muscular dystrophy (166)
Earnings (36500)
Editorial (30)
Employer branding (13)
Employer resources (77)
Events (56564)
Executive appointments (577)
FDA (10475)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (7)
Frontotemporal dementia (17)
Funding (1095)
Gene editing (114)
Generative AI (32)
Gene therapy (324)
GLP-1 (534)
Government (2952)
Grass and pollen (1)
Guidances (251)
Healthcare (10789)
Hematology (179)
HIV (78)
Huntington's disease (21)
IgA nephropathy (51)
Immunology and inflammation (205)
Immuno-oncology (116)
Indications (167)
Infectious disease (1387)
Inflammatory bowel disease (137)
Inflation Reduction Act (7)
Influenza (77)
Intellectual property (183)
Interviews (186)
IPO (7727)
IRA (21)
Job creations (1329)
Job search strategy (883)
JPM (34)
Kidney cancer (27)
Labor market (27)
Layoffs (285)
Leadership (25)
Legal (3951)
Licensing (10)
Liver cancer (111)
Longevity (15)
Lung cancer (945)
Lymphoma (474)
Machine learning (44)
Management (25)
Manufacturing (644)
Marketing (9)
MASH (138)
Medical device (4381)
Medtech (4473)
Mergers & acquisitions (8542)
Metabolic disorders (839)
mRNA (164)
Multiple sclerosis (115)
NASH (8)
Neurodegenerative disease (202)
Neuropsychiatric disorders (51)
Neuroscience (1800)
NextGen: Class of 2026 (3369)
Non-profit (2904)
Now hiring (17)
Obesity (360)
Opinion (197)
Ovarian cancer (260)
Pain (119)
Pancreatic cancer (389)
Parkinson's disease (182)
Partnered (21)
Patents (391)
Patient recruitment (538)
Peanut (20)
People (26207)
Pharmaceutical (17)
Pharmacy benefit managers (24)
Phase 1 (15547)
Phase 2 (19916)
Phase 3 (14612)
Pipeline (7005)
Policy (161)
Postmarket research (1330)
Preclinical (6514)
Press Release (18)
Prostate cancer (374)
Psychedelics (25)
Radiopharmaceuticals (360)
Rare diseases (628)
Real estate (2169)
Recruiting (33)
Regulatory (14351)
Reports (23)
Research institute (1748)
Resumes & cover letters (178)
Rett syndrome (7)
RNA editing (12)
RSV (41)
Schizophrenia (89)
Series A (182)
Series B (123)
Service/supplier (3)
Sickle cell disease (63)
Special edition (12)
Spinal muscular atrophy (77)
Sponsored (32)
Startups (1755)
State (1)
Stomach cancer (21)
Supply chain (67)
Tariffs (44)
The Weekly (47)
Vaccines (582)
Venture capital (55)
Weight loss (199)
Women's health (88)
Worklife (7)
Date
Today (48)
Last 7 days (238)
Last 30 days (1336)
Last 365 days (17356)
2026 (11295)
2025 (17287)
2024 (19898)
2023 (22475)
2022 (28480)
2021 (29837)
2020 (28303)
2019 (24935)
2018 (18523)
2017 (16572)
2016 (15319)
2015 (17718)
2014 (12886)
2013 (10436)
2012 (10969)
2011 (11295)
2010 (10347)
Location
Africa (379)
Alabama (30)
Alaska (5)
Arizona (154)
Arkansas (7)
Asia (22852)
Australia (4186)
California (7843)
Canada (2311)
China (1197)
Colorado (327)
Connecticut (337)
Delaware (301)
Europe (51718)
Florida (1257)
Georgia (200)
Hawaii (2)
Idaho (26)
Illinois (718)
India (76)
Indiana (388)
Iowa (17)
Japan (395)
Kansas (87)
Kentucky (37)
Louisiana (26)
Maine (20)
Maryland (920)
Massachusetts (5404)
Michigan (123)
Minnesota (321)
Mississippi (3)
Missouri (90)
Montana (24)
Nebraska (8)
Nevada (66)
New Hampshire (48)
New Jersey (2598)
New Mexico (18)
New York (2398)
North Carolina (911)
North Dakota (2)
Northern California (4188)
Ohio (181)
Oklahoma (4)
Oregon (17)
Pennsylvania (1511)
Puerto Rico (21)
Rhode Island (23)
South America (555)
South Carolina (18)
South Dakota (1)
Southern California (3061)
Tennessee (155)
Texas (1663)
United States (28452)
Utah (198)
Vermont (1)
Virginia (165)
Washington D.C. (41)
Washington State (788)
West Virginia (3)
Wisconsin (115)
Wyoming (2)
354,620 Results for "pancreatic cancer action network".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Aignostics Partners with the Pancreatic Cancer Action Network to Advance Pancreatic Cancer Research
June 9, 2026
·
4 min read
Pancreatic cancer
‘WOW!’: RevMed and Tango’s pancreatic cancer combo achieves 92% response
After Revolution Medicine’s groundbreaking data drop in April, its Tango-partnered combination approach has demonstrated what analysts called “unprecedented” results for 12 patients with pancreatic cancer, teeing up a late-stage study.
June 8, 2026
·
2 min read
·
Gabrielle Masson
Pancreatic cancer
Verastem deprioritizes pancreatic cancer work after ‘decent, but not great’ data shadowed by Revolution
Following the mid-stage readout, Verastem Oncology has decided to move away from its investigational pancreatic cancer drug combo, instead putting resources behind its KRAS inhibitor pill for solid tumors.
June 18, 2026
·
1 min read
·
Tristan Manalac
Pancreatic cancer
ASCO: Revolution poised to capture RAS space as pancreatic cancer dataset ‘derisks’ approval
Revolution Medicines and its RAS inhibitor daraxonrasib stole the show at the American Society of Clinical Oncology’s annual meeting this weekend, as Truist Securities predicts a possible third quarter launch for the pancreatic cancer drug.
June 1, 2026
·
3 min read
·
Brianna Abbott
Pancreatic cancer
Can Revolution’s ‘miracle’ pancreatic cancer drug be topped? Immuneering, Actuate say yes
Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve on that result with increased tolerability—and more time for patients.
May 18, 2026
·
7 min read
·
Heather McKenzie
Pancreatic cancer
Revolution rises 40% as pancreatic cancer drug doubles survival
In a difficult disease, Revolution Medicines achieved what the pancreatic cancer community has long desired: a significant improvement in survival. The Phase 3 results will support global regulatory filings.
April 13, 2026
·
2 min read
·
Annalee Armstrong
Pancreatic cancer
Revolution levels legal threat on Erasca as pancreatic cancer rivalry heats up
Fresh off a major clinical win, Revolution Medicines alleges that Erasca’s pancreatic cancer drug infringes on key patent protections and that the rival has “improperly compared” the companies’ assets publicly.
April 28, 2026
·
3 min read
·
Tristan Manalac
FDA
FDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum
Fallout from the resignation of FDA Commissioner Marty Makary continues as several other senior regulators are removed from their posts; pharma’s top paid CEOs make up to 358 times more than their employees; Revolution Medicine’s pancreatic cancer results highlight movement in the deadly disease space; more.
May 20, 2026
·
1 min read
·
Jef Akst
Press Releases
Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer
August 17, 2026
·
6 min read
Funding
Revolution doubles stock offering target to $2B following pancreatic cancer win
After Revolution Medicines’ drug candidate doubled survival in a Phase 3 pancreatic cancer study, the biotech is hoping to attract more investor money, with new plans for a $2 billion stock and debt offering.
April 16, 2026
·
1 min read
·
Tristan Manalac
1 of 35,462
Next
